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Abstract: Genome-wide association studies (GWAS) have been successful in the 
identification of the several urinary bladder cancer (UBC) susceptibility loci, pointing 
towards novel genes involved in tumor development. Despite that, functional characterization 
of the identified variants remains challenging, as they mostly map to poorly understood, 
non-coding regions. Recently, two of the UBC risk variants (PSCA and UGT1A) were 
confirmed to have functional consequences. They were shown to modify bladder cancer risk 
by influencing gene expression in an allele-specific manner. Although the role of the other 
UBC risk variants is unknown, it can be hypothesized—based on studies from different 
cancer types—that they influence cancer susceptibility by alterations in regulatory 
networks. The insight into UBC heritability gained through GWAS and further functional 
studies can impact on cancer prevention and screening, as well as on the development of 
new biomarkers and future personalized therapies.  
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1. Introduction 
For many years, the identification of disease-susceptibility genes was based on linkage studies in 
high-risk families. Although rare, high-penetrance mutations have been identified, most of the genetic 
susceptibility in sporadic cases remained unexplained. Recently, however, genome-wide association 
studies (GWAS) have been performed for many complex diseases, including cancer. Cancer is a 
multifactorial disease, arising from the complex interplay between genetic and environmental factors. 
The GWAS approach allows a search for novel susceptibility loci throughout the genome in a 
hypothesis-free manner [1]. Most of the identified variants are common and confer small risk  
(odds ratios between 1.1 and 1.3). However, the involvement of many low-penetrance loci can explain 
differences in cancer susceptibility between individuals [2]. Despite the large number of identified risk 
variants, only a modest number of functional studies have so far been published. The majority of 
identified genetic variants map to non-coding regions in the genome and require fine-mapping, and 
therefore finding the causative variants, as well as understanding their functionality and role in cancer 
development, remains challenging [3]. 
Urinary bladder cancer (UBC) is a common malignancy of the urinary tract, with 180,500 estimated 
new cases each year and 38,200 deaths in the European Union [4], and with 73,510 estimated new 
cases and 14,880 deaths in United States [5]. Despite many years of research and the identification  
of several genes involved in bladder cancer pathogenesis, the large part of its heritability remains 
unknown [6]. In the past, many hypothesis-driven candidate gene studies were performed. However 
the majority of results were not reproduced, with the exception of GSTM1 and NAT2 [1]. GWAS has 
successfully identified several bladder cancer risk variants. Understanding the functional consequences 
of these single nucleotide polymorphisms (SNPs) will help in understanding the role of the identified 
variants in bladder carcinogenesis. This can lead to the development of new biomarkers or therapies 
for selected patients, making personalized medicine for bladder cancer reality [7]. 
The aim of this review is to give a comprehensive overview of the bladder cancer risk of SNPs and 
the functional consequences of these genetic variants. We will include some functional studies 
performed for the risk SNPs that are located in UBC susceptibility regions, but were performed in 
relation to other cancer types. Finally, we will suggest some future research lines that will improve our 
understanding of the heritability underlying UBC. 
2. Bladder Cancer 
Urinary bladder cancer occurs frequently, with the highest incidence rates in developed countries. It 
is typically diagnosed in older patients (55 years of age or older) [8]. Up to 95% of the patients develop 
urothelial cell carcinoma. The remaining types include adenocarcinoma, squamous cell carcinoma and 
other rare histological types [9]. Urothelial cell carcinoma also can include such histological variants, 
which can influence prognosis [10]. About 75% of patients are diagnosed with non-muscle-invasive 
bladder cancer (NMIBC), containing the clinical stages Ta, T1 and CIS (carcinoma in situ). The Ta 
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stage is characterized by the presence of noninvasive papillary lesions of low and high grade, of which 
the latter tends to recur most frequently. T1 tumors invade into the subepithelial connective tissue but 
not into the muscle layer. T1 tumors harbor a higher risk of progression to muscle-invasive disease, 
and even come into consideration for cystectomy. CIS is a flat high-grade lesion and has a higher 
progression rate to muscle invasive bladder cancer (MIBC) [11]. The treatment of NMIBC involves 
the removal of the tumor by transurethral resection (TUR). Surgical removal is usually followed by 
one, or a course of intravesical installations of chemotherapy or immunotherapy, which reduce the risk 
of recurrence. However, the impact on progression and cancer-specific survival remains uncertain [12].  
The remaining 25% of patients are diagnosed with MIBC (T2 stage or higher). Due to the high rate 
of progression to metastatic disease, MIBC, if still confined to the bladder, is mostly treated by radical 
cystectomy [13], but systemic chemotherapy, and radical radiotherapy are also widely used in some 
countries [14].  
The main risk factor for developing bladder cancer is tobacco smoking, accounting for an estimated 
50% of cases among men and 35% of cases among women [15]. Smoking cessation reduces the risk of 
developing bladder cancer immediately. However, due to the fact that many carcinogens are present in 
tobacco smoke, which alter gene expression and damage the DNA, the increased risk is still present 
even after 25 years [16]. Bladder cancer risk is also correlated with various occupational (mainly 
aromatic amines) and environmental exposures (e.g., arsene in drinking water). Other risk factors 
include exposure to ionizing radiation, chronic inflammation or schistosomiasis [17].  
3. Genome-Wide Association Studies  
The environmental risk factors for developing bladder cancer, such as smoking, are common, 
although only a fraction of people exposed to them will eventually suffer from this disease. This 
suggests the contribution of genetic variation in determining bladder cancer risk [18]. In recent years, 
GWAS have emerged as a powerful approach in the discovery of genetics underlying complex traits  
like cancer. 
3.1. Principle of GWAS 
Until now, over 1500 genome-wide association studies have been performed [19], allowing to test, 
in an unbiased way, the most common genetic variation (SNPs) for the association with particular, 
complex traits. GWAS is usually based on the case-control design. Both controls and cases affected by 
the particular trait of interest are genotyped for a large set of SNPs (tagSNPs), spaced across the 
genome, using commercial chips. These proxy markers represent the regions of strong linkage 
disequilibrium (LD), characterized by a high correlation (r2 > 0.8) between SNPs. Therefore, 
genotyping of particular tagSNPs can give information about other SNPs in high LD with the 
measured one. Because of the large number of analyzed loci there will be many false positive findings 
in the discovery set. Particular standards have been adopted in the field. For example, all identified 
variants must reach the genome-wide significance threshold (p < 5 × 10−8) and the association of 
identified variants needs to be confirmed in independent replication sets of cases and controls. 
Additionally, data from several GWAS studies can be pooled in meta-analysis leading to the discovery 
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of variants with even smaller effect sizes. Typically, GWAS examine hundreds of thousands of SNPs 
in at least a thousand cases and a thousand controls, and replicate in series that are even larger [20]. 
3.2. GWAS for Bladder Cancer Risk 
So far, three GWAS for UBC risk have been conducted. Firstly, a European GWAS was led by the 
Radboud University Nijmegen Medical Center (The Netherlands) and deCODE Genetics (Iceland), 
resulting in the identification of 3 UBC risk loci. The three identified loci are located in TP63 
(rs710521), MYC (rs9642880) [21] and FGFR3/TACC3 (rs798766) [22]. The second GWAS was 
conducted by the MD Anderson Cancer Center (USA) leading to the discovery of a SNP in the PSCA 
locus (rs2294008) [23]. The US National Cancer Institute performed a third GWAS, in which  
three susceptibility loci were revealed: CBX6/APOBEC3A (rs1014971), CCNE1 (rs8102137), and 
UGT1A (rs11892031). The association of NAT2 variants and the GSTM1 deletion, discovered through 
candidate gene studies (see above), were confirmed [24]. The association of the SLC14A1 locus was 
independently reported by two groups: Rafnar et al. [25] and Garcia-Closas et al. [26]. Finally, 2 SNPs 
in the TERT-CLPTM1L region (rs2736098; rs401681), previously identified by a GWAS for basal 
carcinoma of the skin, were also found to be associated with the risk of UBC by targeted genotyping of 
selected variants [27]. A summary of all identified UBC risk loci is shown in Table 1. 




Location MAF OR (95% CI) Study type Ref. 
8q24 MYC rs9642880 [T] Intergenic 0.45 1.22 (1.15–1.29) GWAS [21] 
3q28 TP63 rs710521 [A] Intergenic 0.73 1.19 (1.12–1.27) GWAS [21] 
5p15 CLPTM1L rs401681[C] Intronic 0.53 1.12 (1.06–1.18) Follow-up GWAS [27] 
5p15 TERT rs2736098 [A] Exonic 0.25 1.16 (1.08–1.23) Follow-up GWAS [27] 
8q24 PSCA rs2294008 [T] Exonic 0.46 1.15 (1.10–1.20) GWAS [23] 
4p16 FGFR3/TACC3 rs798766 [T] Intronic 0.19 1.24 (1.17–1.32) GWAS [22] 
22q13 CBX6/APOBEC3A rs1014971 [C] Intergenic 0.38 0.88 (0.85–0.91) GWAS [24] 
19q12 CCNE1 rs8102137 [C] Intergenic 0.33 1.13 (1.09–1.17) GWAS [24] 
2q37 UGT1A rs11892031 [C] Intronic 0.08 0.84 (0.79–0.89) GWAS [24] 
18q12 SLC14A1 rs17674580 [T] Intronic 0.33 1.17 (1.11–1.22) GWAS [25] 
18q12 SLC14A1 rs7238033 [T] Intronic 0.43 1.20 (1.13–1.28) Meta-analysis [26] 
1p13 GSTM1 Null * – 0.51 1.5 (1.3–1.6) Candidate gene,  
meta-analysis 
[28] 
8p22 NAT2 Slow acetylator * – 0.56 1.4 (1.2–1.6) Candidate gene,  
meta-analysis 
[28] 
* NAT2 slow acetylator and GSTM1 null refer to the risk genotypes not the risk SNPs; MAF: Minor allele frequency; 
OR: Odds ratio; CI: Confidence intervals. 
4. Functional Studies of Risk SNPs in Bladder Cancer 
Although GWAS have led to discovery of several UBC risk variants, evaluating the role of these 
SNPs remains challenging. Firstly, the identified variants are unlikely causative by themselves, 
therefore further fine-mapping, in search of stronger associated variants in the identified region, needs 
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to be performed. Secondly, the SNPs are located mostly in the intronic and intergenic regions, and 
their role is still poorly understood [3]. Until now, only two of the UBC risk loci have been 
functionally characterized. 
4.1. rs2294008 (PSCA) 
The prostate stem cell antigen (PSCA) gene encodes the glycosylphosphatidylinositol  
(GPI)-anchored cell surface protein belonging to the Thy-1/Ly-6 family. PSCA is expressed in a variety 
of normal tissues including prostate, kidney, skin, esophagus, stomach and placenta. Alterations in 
PSCA expression were described in prostate cancer, renal cell carcinoma, pancreatic cancer, ovarian 
cancer, non-small-cell lung carcinoma, esophageal and gastric cancer [29]. In normal urothelium, 
PSCA is expressed at low levels and the gene is highly over-expressed in the majority of NMIBC and  
MIBC [30]. Although PSCA function is unknown, other members of the Thy-1/Ly-6 family, including 
PSCA, have been implicated in tumorigenesis. They are involved in cell adhesion, signal transduction, 
apoptosis, or T cell activation. It is hypothesized that PSCA may regulate self-renewal and 
proliferation of progenitor/stem cells [31]. Because of frequent PSCA over-expression in both primary 
and metastatic prostatic cancer, PSCA was chosen as a target for immunotherapy. It was shown that 
anti-PSCA antibodies are able to inhibit tumor development by reducing tumor growth and metastasis. 
However, the precise role of PSCA in this process remains to be determined [32].  
The rs2294008 (C/T) SNP, located in the 8q24.3 region is, until now, the most well-studied bladder 
cancer susceptibility variant. This missense variant is located in exon 1 of PSCA and causes a change 
of a nucleotide in the initiation codon. As a result, a novel ATG is used for translation initiation, 
leading to expression of a protein 9 amino acids (aa) longer (Figure 1).  
Figure 1. (a) PSCA locus and location of rs2294008; (b) Influence of rs2294008 on PSCA 
protein length. 
 
Rs2294008 has been identified previously to be associated with diffuse-type gastric cancer in the 
Japanese population. It was shown that the risk T allele reduced PSCA transcriptional activity, 
however no difference in the protein localization between haplotypes containing either the C or T 
allele was observed [33]. By contrast, a study by Tanikawa et al. showed that rs2294008 altered 
cellular localization and stability of PSCA in an allele-specific manner [34]. In bladder cancer cell 
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lines, all haplotypes containing the risk T allele were shown to have reduced PSCA promoter activity, 
in comparison to the non-risk C allele, confirming the aforementioned results. These data suggest that 
the SNP in exon 1 of PSCA is also important for the transcription initiation of PSCA by, for example, 
affecting the binding of transcription factors (TFs) in an allele-specific manner. Unfortunately, no 
correlation of rs2294008 with PSCA mRNA expression was detected in bladder cancer cell lines [23]. 
To study tissue-specific gene regulatory effects, Fu et al. evaluated the PSCA mRNA expression in 
normal bladder and bladder cancer tissue specimens. Surprisingly, the risk T allele was found to be 
correlated with increased PSCA mRNA expression in both tissue types. Moreover, PSCA mRNA 
expression was also found to be strongly up-regulated in bladder cancer samples in comparison to 
adjacent normal tissue. Additionally, the authors fine-mapped the 8q24 region by imputation, and 
found a second variant (rs2978974) located in the alternative exon 1 of PSCA. This variant was found 
to be associated with UBC, although this still has to be confirmed in an independent replication series [35]. 
Rs2294008 was shown to be associated with allelic expression imbalance in normal and tumor 
samples, which are heterozygous for rs2294008. In normal and tumor tissue, transcripts containing the 
T allele were far more abundant than transcripts containing the C allele. On the protein level, cells 
transfected with allele-specific PSCA constructs showed higher PSCA cell surface expression when the 
risk T allele was present. Importantly, rs2294008 was also found to be strongly associated with PSCA 
protein expression levels in a large set of bladder tumors.  
Taken together, the functional studies of PSCA variants indicate that PSCA is subjected to  
allele-specific regulation by rs2294008. The results suggest the possibility of a genotype-based patient 
selection for PSCA immunotherapy [36]. However, the role of PSCA in bladder cancer as well as the 
mechanism by which rs2294008 affects PSCA mRNA expression is unknown. Recently, the concept of 
the androgen-sensitive bladder cancer including PSCA and rs2294008 was proposed. Firstly, UBC  
is diagnosed 3–4 times more frequently in men, but female gender is associated with a worse  
prognosis [37]. Secondly, studies in mice indicated that gender-specific differences in bladder cancer 
susceptibility may be regulated by androgen signaling. It was shown that, when exposed to aromatic 
amines, male mice were more susceptible for bladder cancer than females and castrated males. None of 
androgen receptor (AR) knockout (ARKO) mice developed bladder tumors [38]. Although reports 
about AR expression in bladder cancer are conflicting [39] and rs2294008 is located outside of the 
androgen responsive element (ARE) mapped within the PSCA promoter, it can be hypothesized that 
other variants linked to rs2294008 can influence bladder cancer risk by lowering affinity of the AR to 
ARE in the PSCA promoter region. This event can possibly predispose cancer cells to escape from 
androgen regulation, leading to more aggressive and metastatic disease [40]. This hypothesis remains 
to be proven, but the possible influence of androgens on bladder cancer development and progression 
may lead to the future development of new therapies targeting hormonal signaling [41]. 
4.2. rs17863783 (UGT1A)  
The UDP-glucuronosyltransferase (UGT) 1A locus is located on chromosome 2q37. This complex 
gene is subjected to extensive alternative splicing, leading to the presence of at least nine functional 
isoforms. Each isoform has a unique alternative exon 1, whilst exons 2–5 are shared among all 
isoforms [42]. The UGT1A isoforms are expressed in the majority of tissues, including the liver, 
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kidney, gastrointestinal tract, and the urinary bladder [43]. The UGT1A family is involved in the 
detoxification of many endogenous (steroids, bilirubin) and xenobiotic (drugs, carcinogens) substrates, 
mainly in the liver but also in extrahepatic tissues [44]. They are involved in inactivation of aromatic 
amines through glucoronidation, which increases the solubility and excretability of these compounds. 
However, the N-glucoronidation facilitated by UGT1A is reversible in the acidic urine, leading to the 
accumulation of aromatic amines in the urothelium and formation of DNA mutagenic adducts which 
contribute to carcinogenesis [45]. Moreover, exposure to aromatic amines (e.g., by smoking and 
certain occupations) is a known risk factor for developing bladder cancer [46]. Genetic variants in the 
aromatic amines detoxification enzymes have been identified to be associated with bladder cancer risk, 
including the GSTM1 deletion (null genotype) and the NAT2 slow acetylator genotypes [28]. 
Additionally, genetic variants in UGT1A have been implicated in the modulation of toxicity of the 
chemotherapeutic agent irinotecan, influencing the clinical outcome of treatment [47].  
One of bladder cancer susceptibility loci maps to UGT1A. Rs11892031 (A/C), located in intron 1 of 
UGT1A8 and UGT1A10, has been discovered by Rothman et al. [24]. In follow-up studies, fine-mapping 
of the region was performed by re-sequencing, leading to the identification of a causative genetic 
variant rs17863783 (G/T), which explained the association in this region found by GWAS. This 
synonymous variant is located in the long isoforms of UGT1A6 (UGT1A6.1) (Figure 2). 
Figure 2. UGT1A locus and location of the functional UBC variant. 
 
Although this variant does not change the amino acid sequence, Tang et al. hypothesized that it can 
modify the UGT1A6.1 expression level by influencing the exonic splicing enhancer (ESE) in an  
allele-specific manner. In an in vitro experiment, the presence of the protective T allele caused a 
significant increase in UGT1A6.1 expression, compared to the G allele. Due to the fact that no carriers 
of the uncommon T allele (MAF = 0.025) were detected in bladder samples, rs17863783 was 
correlated with UGT1A6.1 expression in normal liver samples. The protective T allele was found to be 
correlated with increased expression of UGT1A6.1. The increased expression of UGT1A6 in bladder 
tissue can lead to enhanced removal of carcinogens dissociated from glucoronids from bladder tissue 
into the urine, thereby reducing bladder cancer risk [48].  
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Several studies have shown the importance of enzymes involved in the detoxification of aromatic 
amines and other carcinogens in bladder cancer susceptibility [49]. Tang et al. have provided compelling 
evidence that a variant in the UGT1A6.1 gene is functional and affects RNA splicing and gene 
expression in an allele-specific manner. This effect of a genetic variant on UGT1A6.1 gene expression 
may lead to enhanced detoxification of the bladder tissue and therefore to a reduced bladder cancer risk.  
4.3. Functional Studies of Risk SNPs in UBC Susceptibility Regions 
4.3.1. MYC Locus on 8q24 
The v-myc myelocytomatosis viral oncogene homolog (MYC) gene is one of the most well-studied 
proto-oncogenes. This transcription factor regulates hundreds to thousands of genes involved in a wide 
variety of biological processes, both in normal and malignant cells [50]. MYC is known to influence 
proliferation, apoptosis, differentiation, self-renewal/senescence and angiogenesis [51]. It is also one of 
the most frequently up-regulated genes in cancer, suggesting its importance in tumorigenesis [52]. 
Increased MYC expression in tumors was found to be caused by different mechanisms, including MYC 
gene amplification, chromosomal translocations, changes in the MYC regulatory network, and mutations 
targeting the upstream signaling pathways or MYC protein stability [53]. 
The MYC gene is located in the 8q24 region, in which several susceptibility loci were identified  
by GWAS for many epithelial cancers including colorectal cancer [54], prostate cancer [55], breast  
cancer [56] and bladder cancer. The bladder cancer susceptibility variant rs9642880 (G/T) is located 
30 kb upstream of the MYC gene and is in weak LD with the other risk variants on the 8q24. No 
correlation of rs9642880 with MYC expression was detected in whole blood or adipose tissue. It is, 
however, possible that the MYC regulatory mechanism, which may be modified by rs9642880, is 
tissue-specific and therefore detectable only in urothelium [21]. The association of rs9642880 was 
replicated in a Chinese population and it was shown that the risk T allele was correlated with increased 
MYC mRNA expression in normal bladder tissue and protein expression in tumors [57]. These data 
suggest that this variant or a variant in high LD is indeed functional. Until now, no functional studies 
of rs9642880 have been published. On the other hand, several functional studies have been performed 
on SNPs that are scattered over a 500 kb region upstream of the MYC gene, and that are associated 
with several cancer types. No transcriptional (i.e., promoter) activity of the 8q24 risk-alleles was 
detected in colorectal, prostate or breast cancer. However, it was shown that the risk loci, located far 
upstream of MYC, were shown to physically interact with the MYC promoter in a tissue-specific 
manner, possibly influencing MYC expression levels [58]. Furthermore, the risk variants lie within regions 
containing chromatin marks for regulatory elements and were shown to act as enhancers [59,60]. The most 
extensively studied genetic variant in the 8q24 gene desert upstream of MYC gene is the colorectal and 
prostate cancer risk SNP rs6983267. It was shown that rs6983267 maps to a highly conserved TCF4 
transcription factor binding site within a functional enhancer region (MYC-335). TCF4 is known to 
play a role in Wnt signaling (frequently deregulated in colorectal cancer) and MYC is one of the target 
genes of the Wnt signaling pathway [61]. Indeed, TCF4 binding at rs6983267 was found to be  
allele-specific, with increased affinity to the risk G allele. The rs6983267 region was found to be able 
to interact with the MYC promoter via chromatin looping, but no difference in efficiency of chromatin 
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looping between alleles was observed. Conversely, rs69833267 was found to regulate enhancer 
activity in an allele-specific manner in vitro [62,63] and in vivo in transgenic mice [64]. Despite the 
reported enhancer activity of the rs6983267 locus, no correlation with MYC expression has been found 
so far, neither in colorectal nor in prostate cancer tissue samples [65]. Interestingly, Sur et al. showed 
that the presence of the MYC-355 enhancer, containing rs6983267, is not crucial for normal intestinal 
development and function. Surprisingly, MYC-355 only seems to be involved in tumorigenesis, as lack of 
the enhancer region reduced the formation of polyps in an Apcmin mouse strain that spontaneously 
develops colorectal tumors [66]. 
Studies in the other cancer types show that the risk variants at the 8q24 are able to affect MYC 
promoter activity in an allele-specific manner, by influencing transcription factors binding affinity. It is 
therefore reasonable to hypothesize that rs9642880 lies within such a regulatory region and that altered 
TFs binding may modify MYC expression in a similar way. Given that frequent MYC over-expression 
or amplification has been described in bladder cancer [67], MYC seems to play an important role in 
bladder cancer development. Many therapies targeting MYC expression, function, or interaction with 
other proteins, are currently being developed [68]. Thus, future studies elucidating the role of MYC and 
rs9642880 in bladder cancer may have an impact on the selection of patients who may benefit from 
MYC-targeted therapies. 
4.3.2. TERT/CLPTM1L Locus on 5p15 
Multiple studies linked numerous variants at the 5p15 region to cancer risk, including breast cancer, 
pancreatic cancer, and glioma [69]. Furthermore, two bladder cancer risk variants in the 5p15 were 
discovered including rs2736098, a synonymous variant located in the exon of the TERT gene and 
rs401681 in intron 4 of CLPTM1L. Additionally, both variants were found to be associated with 
increased risk of basal cell carcinoma, lung cancer and cervical cancer, which are known to be strongly 
connected to environmental exposures. Interestingly, rs401681 was identified as a protective variant 
for melanoma [27].  
Telomerase is a ribonucleoprotein, which consists of the integral telomerase RNA (TER) and 
telomerase reverse transcriptase (TERT). Telomerase prevents loss of the chromosomal ends, which 
occurs during DNA replication. This, in turn, ensures genome stability and integrity. In normal cells 
telomerase is expressed at low levels and it is tightly controlled through transcriptional and epigenetic 
regulation. The expression of telomerase decreases with subsequent cell divisions, leading to an increase in 
telomeres shortening. Telomere shortening eventually leads to senescence and apoptosis [70,71]. The 
balance between telomere shortening and maintenance is known to influence cancer risk [72]. 
Remarkably, telomerase (TERT) expression is deregulated in approximately 85% of cancers, through 
TERT amplification or 5p chromosomal gains. The up-regulation of TERT expression leads to 
maintenance of telomeres length, resulting in unlimited proliferation and immortalization of cancer 
cells, one of the hallmarks of carcinogenesis [73]. A second gene in the 5p15 locus, upstream of TERT 
is, the less-studied cleft lip and palate transmembrane protein 1-like protein (CLPTM1L). CLPTM1L 
was shown to influence the sensitivity of ovarian cancer cells to cisplatin-induced apoptosis [74]. It 
was also found to be over-expressed in doxorubicin-resistant breast cancer, although the mechanism by 
which CLPTM1L affects drug resistance is unknown [75]. 
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Based on the importance of TERT in carcinogenesis, several studies aimed to evaluate the influence 
of discovered variants. In prostate cancer, fine-mapping of the original GWAS signal was performed, 
leading to the identification of four distinct TERT regions independently associated with prostate 
cancer risk. Interestingly, the identified regions were found to be located within the active regulatory 
elements predicted by The Encyclopedia of DNA Elements (ENCODE). Additionally, SNPs in one of 
the identified risk regions influenced TERT mRNA expression in benign prostate tissue [76]. In the 
previously mentioned study by Rafnar et al. the risk alleles of the two identified SNPs were found to 
be correlated with a shorter length of telomeres in blood of older, but not younger, women. It was 
therefore hypothesized that risk variants may affect telomere length gradually over time, leading to 
increased genomic instability of proliferating cells [27]. The telomere length is known to modify 
bladder cancer risk and is affected by cigarette smoking [77,78]. By contrast, studies in lung cancer 
showed that risk variants in TERT are associated with longer telomeres, possibly promoting tumorigenesis 
by increasing the number of cell divisions, leading to acquisition of more somatic changes in DNA [79]. 
Recent studies in breast and ovarian cancer indicated, however, that regulation of TERT expression and 
the role of the identified risk variants could be much more complex. The risk SNPs in the TERT region 
were shown to differentially influence TERT promoter activity and affect telomere lengths. For 
example, it was shown that some variants did not affect telomere length, but silenced TERT promoter 
activity and led to expression of an alternatively spliced, truncated TERT product [80]. The impact of 
genetic variation on CLPTM1L expression is less studied. Recently, however, it was shown that the 
risk allele of the intronic rs402710 was associated with increased levels of DNA adduct accumulation 
in lung tissue. This suggests that variants identified in CLPTM1L are involved in metabolism of 
carcinogens present in, for example, tobacco smoke [81]. A study by James et al. showed that 
CLPTM1L is frequently over-expressed in lung cancer. In addition, CLPTM1L was shown to play an 
anti-apoptotic role by protecting cancer cells from genotoxic-stress induced DNA damage [82]. 
In conclusion, the 5p15 locus was frequently identified to be associated with increased risk for 
different cancer types, suggesting an important role in cancer etiology. Firstly, it can be hypothesised 
that rs2736098 and/or other variants in LD with rs2736098 can influence TERT transcription levels or 
telomerase activity, leading to increased UBC susceptibility. As new therapies targeting TERT 
signaling are being developed [83], elucidating TERT regulation in UBC is of particular interest. 
Secondly, considering that smoking is a strong risk factor for developing lung and bladder cancer, it is 
possible that the risk variants identified at the 5p15 locus affect the CLPTM1L gene, thereby 
influencing the metabolism of carcinogens, and hence modify cancer risk. So far, functional studies on 
the TERT and CLPTM1L variants in other cancer types have given conflicting data. Therefore, detailed 
studies are needed to evaluate the role of the 5p15 risk SNPs in UBC development and to unravel their 
possible interaction with environmental risk factors. 
5. Future of Functional Studies 
5.1. Possible Role of Variants in Non-Coding Regions 
Until now, the majority of UBC risk variants have not been functionally characterized. However, an 
increasing amount of data is published about the role of the risk variants in modification of cancer 
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susceptibility. Variations in the human genome can influence cellular processes on different levels. 
Exonic genetic variants may affect protein folding, cellular localization, stability, or expression, and 
may disrupt splicing. Intronic and intergenic variants may influence, amongst others, gene expression 
regulation by alterations in transcription factors binding sites, microRNAs sequence or target sites, 
non-coding RNAs or RNA splicing. 
Frequent mutations in the protein coding regions, involved in tumor development, have been 
described in many cancer types [84], including bladder cancer [85]. The majority of GWAS signals 
map to the still poorly understood non-coding regions of the genome. Initiatives like ENCODE proved 
that large parts of the genome, including non-coding regions, are transcribed and probably functional [86]. 
Over 75% of the GWAS risk variants were shown to map to regulatory elements or to be in strong LD 
with SNPs in active regions [87]. Genetic variants regulate gene expression in a cis- (local) and  
trans- (distal) manner, resulting in heritable differences in gene expression levels between individuals, 
which may be found through expression quantitative trait loci (eQTLs) analysis [88]. Several studies in 
different cancer types confirmed that, indeed, the intergenic risk variants map to novel, tissue-specific 
regulatory elements. Furthermore, these SNPs were shown to alter the affinity of transcription factors 
binding, leading to an allelic imbalance in the target gene expression [89–91]. Secondly, it is known 
that long non-coding RNAs (lncRNAs) regulate a large variety of biological processes and play 
important roles in cancer development and, as such, these lncRNAs can act as oncogenes or  
tumor-suppressors [92]. Some risk variants identified by GWAS were found to influence the 
expression of tissue-specific lncRNAs in an allele-specific way [93]. For example, Jendrzejewski et al. 
showed that the non-coding papillary thyroid carcinoma risk variant maps to the novel, thyroid-specific, 
long intergenic non-coding RNA, PTCSC3. The expression of this tumor-suppressor RNA was found 
to be strongly down-regulated in cancer in an allele-specific manner, leading to an increase in cell  
growth [94]. Thirdly, alternative splicing is known to be frequently deregulated in cancer and will lead 
to exon skipping or aberrantly excised intronic sequences [95]. Consequently, altered protein 
expression may influence proliferation, survival and metastatic potential of cancer cells [96]. Several 
SNPs in the exonic and intronic regions were shown to influence the patterns of splicing by altering the 
splicing regulatory sequences, including the exonic and intronic splicing enhancers or silencers. In 
prostate cancer the intronic risk SNP was shown to lie within a splicing enhancer region of the KLF6 
tumor-suppressor gene. This variant was found to increase the transcription of alternatively spliced 
KLF6 isoforms, which act in a dominant-negative way on wild-type KLF6, resulting in increased 
transcriptional activation of growth stimulating genes [97]. Fourthly, microRNAs (miRNAs) are  
post-transcriptional regulators of gene expression and are known to be involved in regulation of a wide 
range of genes and biological processes [98]. Kim et al. showed that SNPs located in miR-1206 at the 
8q24 and miR-612 at the 11q13.3 regions influence the biogenesis of the corresponding mature miRNAs 
in an allele-specific manner [99]. Furthermore, it was shown that in esophageal squamous cell 
carcinoma, a risk SNP in the 3'UTR of the RAP1A gene, affects the binding site of miRNA-196a. This 
led to RAP1A over-expression resulting in more aggressive tumor behavior [100].  
Taken together, the GWAS results suggest that cancer susceptibility is in general modified by the 
alterations or variations in gene expression regulatory mechanisms, rather than by amino acid sequence 
changes. Several diseases have already been linked to mutations in non-coding regions including 
Hirschsprung disease [101], colorectal cancer [102], or melanoma [103,104], pointing towards a 
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crucial role of cis-regulatory regions in health and disease [105]. Considering the rapid development of 
the techniques suitable for analysis of the non-coding regions, as well as the more accurate and more 
comprehensive annotation of tissue-specific regulatory elements, functional studies of the intronic and 
intergenic variants will become more straightforward in the future [106].  
5.2. Rapid Development of New Technologies 
Despite the success of GWAS in the identification of novel risk loci, only a small part of an 
individual’s cancer susceptibility can be explained by genetic variants. The majority of studies so far 
focused on common variants following the “common disease–common variant” hypothesis. With 
improvements in technologies the “missing heritability” problem is expected to be (at least partly) 
solved by the discovery of multiple low-effect size, rare and/or structural variants associated with a 
particular disease [107]. 
Initiatives like The International 1000 Genomes Project will improve the characterization of human 
genome variation by sequencing individuals from different populations, leading to the annotation not 
only common of variants (MAF > 5%), but also low frequency (MAF < 1%) and rare variants  
(MAF < 0.5%) [108,109]. In the past years, genotyping chips allowed for the detection of common 
variants. Recently, new chips have been designed that allow the detection of less common variants. 
However, next generation sequencing, including whole-genome and whole-exome sequencing, are 
emerging as new, powerful tools in the detection of rare variants [110]. It is possible that multiple low 
penetrance variants associated with disease remain to be discovered. Larger GWAS initiatives and 
meta-analyses of the existing data are needed in order to discover the common variants with even 
smaller effects contributing to overall disease susceptibility [111]. Despite improvements in technologies 
that detect copy number variants (CNVs) through SNP arrays, calling of CNVs pose a particular 
challenge. With further developments of methodology and annotation of CNVs our understanding of 
the full spectrum of this variation will become more complete [112]. 
5.3. The Impact of Context 
Until now, the bladder cancer risk loci confer only a small increased risk, suggesting that pathways 
involved in cancer development can be much more complex than expected and that the risk variants 
need to be studied in particular cancer subtypes or environmental context. 
The number of identified risk loci differs significantly between cancer types. This highlights the 
polygenic nature of cancer and the differences in etiology between different tumors. Alternatively, 
some of the tumor types can be more heterogeneous than others, which complicates the discovery of 
more general variants [113]. Secondly, GWAS risk signals show a remarkable subtype specificity. In 
breast cancer, several risk variants were shown to be associated only with the more aggressive  
ER-negative tumors but not with ER-positive cancer, confirming observed differences in clinical 
behavior of both tumor types [114]. Interestingly, several bladder cancer risk variants including  
MYC [21] and FGFR3/TACC3 [22] show stronger association with low risk tumors, confirming the 
heterogeneous nature of bladder cancer [115]. In this regard, identification of pathways affected by 
subtype-specific variants and involved in less or more aggressive disease development will be 
important for cancer prevention. The collection of larger sample sizes corresponding to disease 
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subtypes can result in the identification of more loci which are subtype-specific [116]. Finally, 
interactions between identified SNPs and environmental and lifestyle factors can modify individual 
cancer susceptibility, but this has not yet been extensively studied [117]. Garcia-Closas et al. showed 
that 6 of 12 UBC susceptibility variants showed significant additive gene–environment interactions, 
most notably true for NAT2 and UGT1A6. They also demonstrated how GWAS data can be used for 
predicting the absolute risk of bladder cancer, taking into account smoking [118]. It would be of 
particular interest to study the additive effects of the identified UBC susceptibility variants in other 
environmental and lifestyle contexts, although it requires large sample sizes and above all valid 
phenotypic and exposure information [119]. 
6. Conclusions 
The GWAS approach has been successful in the identification of UBC risk genetic variants. Until 
now, only two of the identified loci (PSCA and UGT1A) have been functionally characterized. These 
studies, however, confirmed that variants identified by GWAS have functional consequences and 
influence gene expression in an allele-specific manner. Furthermore, the GWAS approach pointed 
towards new genes involved in bladder cancer development, possibly leading to the development of 
new therapies in the future. In this regard, the heritable differences in gene expression related to risk 
SNPs have potential to be used in the selection of patients who will benefit from a particular treatment. 
As our understanding of the non-coding regions is still far from complete, the role of other bladder 
cancer risk variants remains unknown. An increasing amount of data is being published about the 
influence of intergenic and intronic SNPs in modification of various biological processes. It can, 
therefore, be hypothesized that UBC risk variants affect gene expression by alterations in  
urothelium-specific regulatory networks through one of the aforementioned mechanisms. A large part 
of UBC susceptibility remains to be uncovered. Bladder cancer occurs frequently and is associated 
with high economic costs, due to extensive follow-up [120]. Screening programs for bladder cancer are 
currently not thought to reduce disease specific outcomes. Tailoring of such programs according to 
genetic risks and patterns of exposure to carcinogens may enable the identification or selection of 
people at risk [121]. Until now, individual genetic risk assessment using the risk variants has not been 
clinically relevant, however, it cannot be excluded that, with increasing numbers of identified variants, 
genetic counseling of high risk groups, based on GWAS results, will become possible [122]. In 
conclusion, GWAS results are very promising in bringing us closer to the era of personalized medicine. 
However, they still pose a particular challenge in the interpretation of their functional significance. 
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